Original language | English |
---|---|
Article number | e12173 |
Journal | Clinical and Translational Allergy |
Volume | 12 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2022 |
Keywords
- children
- exacerbations
- inhaled corticosteroids
- methylation quantitative trait loci (meQTL)
- pharmacogenetics
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Clinical and Translational Allergy, Vol. 12, No. 8, e12173, 08.2022.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Association of bronchial steroid inducible methylation quantitative trait loci with asthma and chronic obstructive pulmonary disease treatment response
AU - Slob, Elise M.A.
AU - Faiz, Alen
AU - van Nijnatten, Jos
AU - Vijverberg, Susanne J.H.
AU - Longo, Cristina
AU - Kutlu, Merve
AU - Chew, Fook Tim
AU - Sio, Yang Yie
AU - Herrera-Luis, Esther
AU - Espuela-Ortiz, Antonio
AU - Perez-Garcia, Javier
AU - Pino-Yanes, Maria
AU - Burchard, Esteban G.
AU - Potočnik, Uroš
AU - Gorenjak, Mario
AU - Palmer, Colin
AU - Maroteau, Cyrielle
AU - Turner, Steve
AU - Verhamme, Katia
AU - Karimi, Leila
AU - Mukhopadhyay, Somnath
AU - Timens, Wim
AU - Hiemstra, Pieter S.
AU - Pijnenburg, Mariëlle W.
AU - Neighbors, Margaret
AU - Grimbaldeston, Michele A.
AU - Tew, Gaik W.
AU - Brandsma, Corry A.
AU - Berce, Vojko
AU - Aliee, Hananeh
AU - Theis, Fabian
AU - Sin, Don D.
AU - Li, Xuan
AU - van den Berge, Maarten
AU - Maitland-van der Zee, Anke H.
AU - Koppelman, Gerard H.
N1 - Funding Information: The GLUCOLD study (for which these are secondary analyses) was supported by the Netherlands Organisation for Scientific Research (NWO), the Dutch Asthma Foundation, GlaxoSmithKline, the University Medical Center Groningen, and Leiden University Medical Center. Genentech Inc. funded the GLUCOLD bronchial biopsy RNA sequencing project. E.M.A. Slob, S.J.H. Vijverberg, A.H. Maitland‐van der Zee, G.H. Koppelman and M.W. Pijnenburg are conducting the PUFFIN trial that is supported by the Lung Foundation Netherlands, grant number 5.1.16.094. The PACMAN cohort study was funded by a strategic alliance between GlaxoSmithKline and Utrecht Institute for Pharmaceutical Sciences. The SLOVENIA study was financially supported by the Slovenian Research Agency (research core funding No. P3‐0067) and from the SysPharmPedia grant, co‐financed by the Ministry of Education, Science and Sport Slovenia (MIZS) (contract number C3330‐16‐500106). The Genes‐environments and Admixture in Latino Americans (GALA II) Study and the Study of African Americans, Asthma, Genes and Environments (SAGE) were supported in part by the Sandler Family Foundation, the American Asthma Foundation, the RWJF Amos Medical Faculty Development Program, Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II, the National Heart, Lung, and Blood Institute of the National Institutes of Health R01HL117004, R01HL128439, R01HL135156, X01HL134589, R01HL141992, R01HL141845, National Institute of Health and Environmental Health Sciences R01ES015794, R21ES24844, the National Institute on Minority Health and Health Disparities P60MD006902, RL5GM118984, R01MD010443, and R56MD013312, the Tobacco‐Related Disease Research Program under Award Number 24RT‐0025, 27IR‐0030 and the National Human Genome Research Institute U01HG009080. The genotyping service of PAGES was carried out at CEGEN‐PRB3‐ISCIII, supported by grant PT17/0019 of the PE I+D+i 2013–2016, funded by ISCIII and ERDF. Maria Pino‐Yanes was funded by the Ramón y Cajal Program by the Spanish Ministry of Science, Innovation, and Universities (MICIU) (RYC‐2015‐17205) and by a grant by MICIU, the State Research Agency, and the European Regional Development Fund from the European Union (MICIU/AEI/FEDER, UE, SAF2017‐83417R). Esther Herera‐Luis was supported by a MICIU fellowship (PRE2018‐083837). Javier Perez‐Garcia was also supported by a Ph.D. fellowship (FPU19/02175) granted by MICIU. Antonio Espuela‐Ortiz was supported by a fellowship granted by MICIU/ULL (M‐ULL). The SLOVENIA study was financially supported by the Slovenian Research Agency (research core funding No. P3‐0067) and from the SysPharmPedia grant, co‐financed by the Ministry of Education, Science and Sport Slovenia (MIZS) (contract number C3330‐16‐500106). F.J. Theis reports receiving consulting fees from Roche Diagnostics GmbH and Cellarity Inc., and ownership interest in Cellarity, Inc. and Dermagnostix. Funding Information: The GLUCOLD study (for which these are secondary analyses) was supported by the Netherlands Organisation for Scientific Research (NWO), the Dutch Asthma Foundation, GlaxoSmithKline, the University Medical Center Groningen, and Leiden University Medical Center. Genentech Inc. funded the GLUCOLD bronchial biopsy RNA sequencing project. E.M.A. Slob, S.J.H. Vijverberg, A.H. Maitland-van der Zee, G.H. Koppelman and M.W. Pijnenburg are conducting the PUFFIN trial that is supported by the Lung Foundation Netherlands, grant number 5.1.16.094. The PACMAN cohort study was funded by a strategic alliance between GlaxoSmithKline and Utrecht Institute for Pharmaceutical Sciences. The SLOVENIA study was financially supported by the Slovenian Research Agency (research core funding No. P3-0067) and from the SysPharmPedia grant, co-financed by the Ministry of Education, Science and Sport Slovenia (MIZS) (contract number C3330-16-500106). The Genes-environments and Admixture in Latino Americans (GALA II) Study and the Study of African Americans, Asthma, Genes and Environments (SAGE) were supported in part by the Sandler Family Foundation, the American Asthma Foundation, the RWJF Amos Medical Faculty Development Program, Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II, the National Heart, Lung, and Blood Institute of the National Institutes of Health R01HL117004, R01HL128439, R01HL135156, X01HL134589, R01HL141992, R01HL141845, National Institute of Health and Environmental Health Sciences R01ES015794, R21ES24844, the National Institute on Minority Health and Health Disparities P60MD006902, RL5GM118984, R01MD010443, and R56MD013312, the Tobacco-Related Disease Research Program under Award Number 24RT-0025, 27IR-0030 and the National Human Genome Research Institute U01HG009080. The genotyping service of PAGES was carried out at CEGEN-PRB3-ISCIII, supported by grant PT17/0019 of the PE I+D+i 2013–2016, funded by ISCIII and ERDF. Maria Pino-Yanes was funded by the Ramón y Cajal Program by the Spanish Ministry of Science, Innovation, and Universities (MICIU) (RYC-2015-17205) and by a grant by MICIU, the State Research Agency, and the European Regional Development Fund from the European Union (MICIU/AEI/FEDER, UE, SAF2017-83417R). Esther Herera-Luis was supported by a MICIU fellowship (PRE2018-083837). Javier Perez-Garcia was also supported by a Ph.D. fellowship (FPU19/02175) granted by MICIU. Antonio Espuela-Ortiz was supported by a fellowship granted by MICIU/ULL (M-ULL). The SLOVENIA study was financially supported by the Slovenian Research Agency (research core funding No. P3-0067) and from the SysPharmPedia grant, co-financed by the Ministry of Education, Science and Sport Slovenia (MIZS) (contract number C3330-16-500106). F.J. Theis reports receiving consulting fees from Roche Diagnostics GmbH and Cellarity Inc., and ownership interest in Cellarity, Inc. and Dermagnostix.
PY - 2022/8
Y1 - 2022/8
KW - children
KW - exacerbations
KW - inhaled corticosteroids
KW - methylation quantitative trait loci (meQTL)
KW - pharmacogenetics
UR - http://www.scopus.com/inward/record.url?scp=85136850046&partnerID=8YFLogxK
U2 - 10.1002/clt2.12173
DO - 10.1002/clt2.12173
M3 - Letter
AN - SCOPUS:85136850046
SN - 2045-7022
VL - 12
JO - Clinical and Translational Allergy
JF - Clinical and Translational Allergy
IS - 8
M1 - e12173
ER -